What is Ascletis Pharma?
Ascletis Pharma Inc. is a fully integrated biotechnology firm focused on the development and commercialization of novel therapeutics for metabolic diseases. Leveraging cutting-edge technologies, including AI-assisted Structure-Based Drug Discovery and an Ultra-Long-Acting Platform, the company is creating a pipeline of drug candidates, encompassing small molecules and peptides, primarily targeting chronic weight management. Ascletis is committed to addressing critical unmet medical needs globally and is publicly traded on the Hong Kong Stock Exchange, serving both healthcare providers and patients with innovative solutions for metabolic and immune conditions.
How much funding has Ascletis Pharma raised?
Ascletis Pharma has raised a total of $255M across 4 funding rounds:
Series A
$100M
Private Equity
$35M
Unspecified
$20M
Series B
$100M
Series A (2011): $100M, investors not publicly disclosed
Private Equity (2015): $35M led by Tasly Pharmaceuticals, Inc and CBC Group
Unspecified (2015): $20M supported by Goldman Sachs Group
Series B (2017): $100M featuring Tasly Pharmaceuticals, Inc, CBC Group, and Goldman Sachs Group
Key Investors in Ascletis Pharma
Tasly Pharmaceuticals, Inc
Tasly Pharmaceuticals, Inc. is a China-based conglomerate with a global presence, primarily focused on pharmaceutical manufacturing and distribution, operating across healthcare, technology, and consulting services.
CBC Group
CBC Group is a leading Asia-focused investment firm specializing in the healthcare sector, with a strategic emphasis on platform-building and buyout opportunities in pharmaceuticals, biotech, medtech, and healthcare services.
Goldman Sachs Group
Goldman Sachs Group is a prominent global investment banking and financial services firm, offering a comprehensive suite of services including advisory, underwriting, asset management, and securities trading.
What's next for Ascletis Pharma?
The substantial enterprise-level capital infusion positions Ascletis Pharma for accelerated development and commercialization of its innovative therapeutic candidates. This strategic financing is expected to fuel advancements in their drug discovery pipeline, particularly in areas like chronic weight management, and support expansion into new markets. The company's focus on advanced technological platforms suggests a trajectory towards significant market penetration and the potential to address widespread unmet medical needs, reinforcing its role as a key player in the biotechnology landscape.
See full Ascletis Pharma company page
